Reports
Global Adderall Drug Market Share, Size, Analysis, Growth, Forecast: By Disease Type: Attention Deficit Hyperactivity Disorder (ADHD), Narcolepsy, Others; By Distribution Channel: Hospital-based Pharmacies, Retail Pharmacies, Others; Regional Analysis; Market Dynamics: Industry Drivers and Constraints; Supplier Landscape; 2023-2031
Global Adderall Drug Market Outlook
The global Adderall drug market size is being driven by the rising prevalence of ADHD, which was close to USD 20.1 billion in 2022. The market is expected to grow with a CAGR of 4% during the forecast period of 2023-2031. The market is expected to reach a value of about USD 28.6 billion by 2031.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Adderall Insights
Adderall is a trade name of the drug amphetamine. It is an FDA-approved prescription drug and first choice treatment option for attention deficit hyperactivity disorder (ADHD). It is also used for the treatment of narcolepsy, a chronic sleep disorder that is characterised by extreme daytime sleepiness and unexpected sleep episodes.
ADHD at a Glance
ADHD is a heterogeneous neurodevelopmental syndrome that comprises hyperactivity, increased impulsivity, and developmentally inappropriate inattentiveness. Multiple aspects of life are greatly hampered by ADHD, which can result in underachievement in school, unemployment, a failed marriage, and criminal activity, among other things.
Additionally, several comorbid mental problems, such as antisocial personality disorder, self-harm, and substance abuse, exhibit substantial correlations with ADHD, inflict significant burden on families and society.
Dosage and Side Effects of Adderall
Usage of Adderall for a prolonged period may lead to dependency or misuse of the drug and resultant adverse cardiovascular events. The effectiveness of Adderall in long-term use has not been evaluated in clinical trials thoroughly, therefore, when prescribed, it is necessary to re-evaluate the efficacy of the drug periodically by physicians.
Contraindications of Adderall are arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, hypersensitivity (idiosyncrasy to sympathomimetics amines, and glaucoma.
Some serious side effects include slow growth in children, seizures, blurred vision, or change in eyesight whereas some common side effects of this drug consist of headache, stomachache, trouble sleeping, decreased appetite, nervousness, and dizziness, among others.
Adderall Drug Market Scenario
The market is further divided into the following segmentations:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Disease Treatment
- Attention Deficit Hyperactivity Disorder (ADHD)
- Necrolepsy
- Others
Market Breakup by Distribution Channel
- Hospital-based pharmacies
- Retail pharmacies
- Others
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Telehealth Prescription Propelling the Adderall Drug Market
The rising demand of Adderall drug market can be attributed to telehealth prescriptions of controlled substances like Adderall and Ritalin by online mental health care startups that were established during the pandemic and were permitted to do so by the US Drug Enforcement Agency.
Global Scenario for Adderall
Globally, ADHD is estimated to be affecting about 5% of children and teenagers. Due to the lack of standardised diagnostic criteria, adult ADHD appears to be overlooked in epidemiology. One of the most commonly given stimulants, along with Adderall are Ritalin and Concerta.
Cognitive and memory enhancer medications, supplements, and other substances are claimed to boost cognitive function in healthy persons, notably executive functions, attention, memory, creativity, or motivation. These medications comprise a variety of compounds that can boost cognitive performance and can increase or retain memory, stimulate learning, or prevent cognitive decline or dementia.
ADHD diagnosis can differ on the basis of age group and gender. Based on age group, the average age of ADHD diagnosis in children in the United States is about seven years, there is an increase of about two times in the cases of ADHD over the past ten years. The first signs and symptoms of ADHD are typically expected to appear between the age group of 3-6 years.
About 4% of adult Americans are dealing with ADHD symptoms on daily basis. Based on gender, the male population is about 3 times more likely to be diagnosed with ADHD than the female population.
Adderall Market Trends
The market is also rising with the rapid increase in the senior population, which is more vulnerable to neurological illnesses, such as Alzheimer's. Increased usage of cognitive medicines due to benefits, such as improved physical and mental performance, drives the market growth further. However, ethical concerns about the use of such pharmaceuticals can limit the market growth.
Therapeutic Landscape of Adderall
ADHD is treated with short, intermediate, and long-acting forms of stimulants. Adderall, being a short-acting stimulant, is usually consumed 2-3 times a day and has better control when it is in the system but it is difficult to keep the dose intake persistent on daily basis.
Amphetamine is a medication that is used to manage and treat ADHD and narcolepsy. It is classified as a stimulant of the central nervous system. Amphetamine has been shown to increase the concentrations of noradrenaline in the prefrontal cortex and dopamine in the striatum in a dose and time-dependent manner. The indistinct release of neurotransmitters such as adrenaline is known to have cardiovascular side effects.
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Intas Pharmaceuticals
- Aztiq Pharma Partners
- Ascent Pharms, Inc.
- Aurolife Pharma LLC
- Cediprof, Inc.
- Elite Labs, Inc.
- PuraCap Pharmaceutical
- Granules Pharmaceutical, Inc.
- Nuvo Pharm
- Shire LLC (Takeda Pharmaceutical Company Limited)
- Rhodes Pharma
- Zydus Lifesciences Limited
- Teva Pharmaceutical
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Global Adderall Drug Overview
4.1 Pharmacodynamics
4.2 Pharmacokinetics
4.3 Adverse Events
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Investment Scenarios
6.5 Regulatory Framework
6.5.1 Regulatory Overview
6.5.1.1 US FDA
6.5.1.2 EU EMA
6.5.1.3 INDIA CDSCO
6.5.1.4 JAPAN PMDA
6.5.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-out Rate
7.3 Awareness and Prevention Gaps
8 Global Adderall Drug Market
8.1 Global Adderall Drug Market Overview
8.2 Global Adderall Drug Market Analysis
8.2.1 Market Overview
8.2.1.1 Adderall Historical Market by Value (2016-2022)
8.2.1.2 Adderall Market Forecast by Value (2023-2031)
8.3 Global Adderall Drug Market by Disease Type
8.3.1 Market Overview
8.3.1.1 Attention Deficit Hyperactivity Disorder (ADHD)
8.3.1.2 Narcolepsy
8.3.1.3 Others
8.4 Global Adderall Drug Market by Distribution Channel
8.4.1 Market Overview
8.4.1.1 Hospital-based Pharmacies
8.4.1.2 Retail Pharmacies
8.4.1.3 Others
8.5 Global Adderall Drug Market by Region
8.5.1 Market Overview
8.5.1.1 North America
8.5.1.2 Europe
8.5.1.3 Asia Pacific
8.5.1.4 Latin America
8.5.1.5 Middle East and Africa
9 North America Adderall Drug Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Adderall Drug Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Adderall Drug Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Adderall Drug Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Adderall Drug Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Adderall Drug Market Dynamics
14.1 Industry Drivers and Constraints
14.2 Adderall Drug Adoption Parameters
14.3 SWOT Analysis
14.4 Porter Five Forces Model
14.5 Key Demand Indicators
14.6 Key Price Indicators
14.7 Value Chain Analysis
15 Global Adderall Drug Market Supplier Landscape
15.1 Intas Pharmacueticals
15.1.1 Company Overview
15.1.2 Product Portfolio - -new product development
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Aztiq Pharma Partners
15.2.1 Company Overview
15.2.2 Product Portfolio - -new product development
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Ascent Pharms, Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Aurolife Pharma LLC
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Cediprof, Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Elite Labs, Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 PuraCap Pharmaceutical
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Granules Pharmaceutical, Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Nuvo Pharm
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Shire LLC (Takeda Pharmaceutical Company Limited)
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Rhodes Pharma
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 Zydus Lifesciences Limited
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
15.13 Teva Pharmaceutical
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
15.13.5 Certifications
16 Pricing Models and Strategies (Additional Insight)
16.1 Cost Model
16.1.1 Manufacturing Cost Analysis
16.1.2 Procurement Cost Analysis
16.2 Pricing Strategies
16.2.1 Competitor pricing Analysis
16.2.2 Key assessment of product attributes
16.2.3 Pricing Benchmark
17 Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key parameters for Distribution Partner Assessment
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of USD 20.1 billion in 2022.
The Adderall market is likely to be driven by the rising prevalence rate of ADHD, which is projected to grow at a CAGR of 4% between 2022 and 2031.
The primary driver driving market expansion is an increase in the senior population, which is predisposed to neurological illnesses such as ADHD.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share in the market.
Adderall is a Schedule II prohibited drug; a prescription is required to buy it.
Body tends to tolerate Adderall and become less effective over time. Medical practitioners are expected to check the efficacy of the drug and range the doses accordingly.
The major players in the industry are Intas Pharmaceuticals, Aztiq Pharma Partners, Ascent Pharms, Inc., Aurolife Pharma LLC, Cediprof, Inc., Elite Labs, Inc., PuraCap Pharmaceutical, Granules Pharmaceutical, Inc., Nuvo Pharm, Shire LLC (Takeda Pharmaceutical Company Limited), Rhodes Pharma, Zydus Lifesciences Limited, and Teva Pharmaceutical, among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER